When PBMCs were pretreated with the TBK1 inhibitors Amlexanox or MRT67307, both inhibitors suppressed DM patients' plasma-derived sEVs-induced IFNβ release in PBMCs via inhibiting TBK1 and its downstream protein IRF3 phosphorylation (Figure 6C-D). The gene discussed is IFNB1; the disease is dermatomyositis.